AZD1208

Name: AZD1208
Brand: MedChemExpress
SKU: HY-15604
Rating: 5.0 (22 reviews)

Cat. No.: HY-15604 Purity: 99.73%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

AZD1208 is an orally bioavailable, highly selective PIM kinases inhibitor.

For research use only. We do not sell to patients.

CAS No. : 1204144-28-4

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	Get quote
1 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 22 publication(s) in Google Scholar

Other Forms of AZD1208:

AZD1208 hydrochloride Get quote

22 Publications Citing Use of MCE AZD1208

Bio/Physico-chemical Assay

RT-PCR

: AZD1208 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 6:e03487. [Abstract]; Protein level of p-STAT1/2 in HEK293T cells treated with PIM1 inhibitor AZD-1208 (0, 2, 4, 8 μM) for 24h followed by the stimulation with/without poly: IC for 16 h, or IFN for 1h.

: AZD1208 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 6:e03487. [Abstract]; PIM inhibitors AZD-1208 (0-12 μM) pre-treated with RD cells for 2h, followed by the OC43 infection for 72h at the MOI of 0.01. OC43 viral RNA were determined.

: AZD1208 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 6:e03487. [Abstract]; PIM inhibitors AZD-1208 (0-12 μM) pre-treated with RD cells for 2h, followed by the OC43 infection for 72h at the MOI of 0.01. OC43 viral N protein was determined.

: AZD1208 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 6:e03487. [Abstract]; Protein level of -TrCP1 in HEK293T cells treated with the indicated concentration of PIM1 inhibitor AZD-1208 (0-12 μM) for 48h.

: AZD1208 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 6:e03487. [Abstract]; Western blot for IFNAR1 expression in HEK293T or HepG2 cells treated with PIM1 inhibitors AZD-1208 (0, 2, 4, 8 μM) for 48 h.

: AZD1208 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Apr 23;10(1):1844. [Abstract]; Primary monocytes were differentiated into macrophages and infected with HIV-2 reporter virus carrying wild-type Vpx or its S13A mutants. A pan-PIM kinase inhibitor AZD1208 (0, 0.1, 0.5 μM) was added 4 h before infection. Fortyeight hours post-infection, cells were harvested and subjected to luciferase assay.

: AZD1208 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Apr 23;10(1):1844. [Abstract]; Primary monocytes were differentiated into macrophages and infected with HIV-2 reporter virus carrying wild-type Vpx or its S13A mutants. A pan-PIM kinase inhibitor AZD1208 (0, 0.1, 0.5 μM) was added 4 h before infection. Fortyeight hours post-infection, cells were harvested and immunoblotting to measure HIV-2 infectivity and SAMHD1 expression.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Pim Isoform Specific Products:

View All Isoforms

PIM1 PIM2 PIM3

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

AZD1208 is an orally bioavailable, highly selective PIM kinases inhibitor^[1].

IC₅₀ & Target

PIM2

Cellular Effect

Cell Line	Type	Value	Description	References
KMS-11	EC₅₀	0.67 μM Compound: 2; AZD1208	Antiproliferative activity against luciferase expressing human KMS11 cells after 72 hrs by Cell-TiterGlo assay Antiproliferative activity against luciferase expressing human KMS11 cells after 72 hrs by Cell-TiterGlo assay	[PMID: 26505898]
WI-38	IC₅₀	>10000 nM Compound: AZD1208	Growth inhibition of human WI38 cells after 48 hrs by CCK8 assay Growth inhibition of human WI38 cells after 48 hrs by CCK8 assay	[PMID: 28523101]
WI-38	IC₅₀	>10 μM Compound: AZD1208	Growth inhibition of human WI38 cells after 48 hrs by CCK8 assay Growth inhibition of human WI38 cells after 48 hrs by CCK8 assay	[PMID: 28523101]

In Vitro

AZD1208 shows good antiproliferative activity in a megakaryoblastic leukemia cell line, MOLM-16, with GI₅₀ values less than 100 nM^[1].
AZD1208 (10 μM) inhibits the growth of Ramos cells, and at 1 μM, strongly inhibits PIM kinases in all cell at 1 μM. AZD1208 induces apoptosis, and PIM2 knockdown is mainly associated with an alteration of the cell cycle^[2].
The combination of AZD1208 and AZD2014 rapidly activates AMPKα, a negative regulator of translation machinery through mTORC1/2 signaling in AML cells; profoundly inhibits AKT and 4EBP1 activation; and suppresses polysome formation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

379.48

Formula

C₂₁H₂₁N₃O₂S

CAS No.

1204144-28-4

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(NC/1=O)SC1=C/C2=C(N3C[C@H](N)CCC3)C(C4=CC=CC=C4)=CC=C2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (131.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6352 mL	13.1759 mL	26.3519 mL
5 mM	0.5270 mL	2.6352 mL	5.2704 mL
10 mM	0.2635 mL	1.3176 mL	2.6352 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (13.18 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 5 mg/mL (13.18 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.73%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (253 KB) HNMR (306 KB) RP-HPLC (266 KB) LCMS (96 KB)

Handling Instructions (2659 KB)

References

[1]. Dakin LA, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4599-604. [Content Brief]

[2]. Kreuz S, et al. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas. Mol Cancer. 2015 Dec 8;14:205. [Content Brief]

[3]. Harada M, et al. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget. 2015 Nov 10;6(35):37930-47. [Content Brief]

Cell Assay
^[1]

MOLM-16 cells, purchased from DSMZ and cultured in RPMI containing 10% fetal bovine serum (FBS) and 1% L-glutamine, are plated at 20,000 cells per well in 96 well plates overnight. Cells are treated for 72 hours with compound or control vehicle (dimethyl sulfoxide) and cell viability is measured after the addition of Cell Titer-Blue for 4 hours at 37°C and reading of fluorescence on a Tecan Infinite^® 200. The GI₅₀ is determined by calculating growth at each dose relative to vehicle treated cells and cell viability at the time of treatment.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Dakin LA, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4599-604. [Content Brief]

[2]. Kreuz S, et al. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas. Mol Cancer. 2015 Dec 8;14:205. [Content Brief]

[3]. Harada M, et al. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget. 2015 Nov 10;6(35):37930-47. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6352 mL	13.1759 mL	26.3518 mL	65.8796 mL
	5 mM	0.5270 mL	2.6352 mL	5.2704 mL	13.1759 mL
	10 mM	0.2635 mL	1.3176 mL	2.6352 mL	6.5880 mL
	15 mM	0.1757 mL	0.8784 mL	1.7568 mL	4.3920 mL
	20 mM	0.1318 mL	0.6588 mL	1.3176 mL	3.2940 mL
	25 mM	0.1054 mL	0.5270 mL	1.0541 mL	2.6352 mL
	30 mM	0.0878 mL	0.4392 mL	0.8784 mL	2.1960 mL
	40 mM	0.0659 mL	0.3294 mL	0.6588 mL	1.6470 mL
	50 mM	0.0527 mL	0.2635 mL	0.5270 mL	1.3176 mL
	60 mM	0.0439 mL	0.2196 mL	0.4392 mL	1.0980 mL
	80 mM	0.0329 mL	0.1647 mL	0.3294 mL	0.8235 mL
	100 mM	0.0264 mL	0.1318 mL	0.2635 mL	0.6588 mL

AZD1208 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

AZD12081204144-28-4AZD 1208AZD-1208PimAutophagyApoptosisPim kinasesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

AZD1208

Customer Review

Other Forms of AZD1208:

AZD1208 Related Antibodies

22 Publications Citing Use of MCE AZD1208

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Pim Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

AZD1208 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

AZD1208 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report